Shares of Bristol-Myers Squibb (NYSE:BMY) rose 0%

Shares of Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) were up 0% during trading on Friday. The company traded as high as $41.14 and last traded at $40.77. 2,787,388 shares traded hands during trading, down 82% from the session’s average volume of 15,586,995 shares. Shares previously closed at $40.75.

Analysts set new price targets

A number of brokerages have recently commented on BMY. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. Barclays cut their price target on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, BMO Capital Markets decreased their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday. April 26. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $59.07, based on data from MarketBeat.

See the latest stock report on Bristol-Myers Squibb

Bristol-Myers Squibb Price Performance

The stock has a 50-day simple moving average of $41.92 and a 200-day simple moving average of $47.36. The company has a current ratio of 1.11, a quick ratio of 0.99, and a debt-to-equity ratio of 2.99. The stock has a market cap of $82.02 billion, a price-to-earnings ratio of -13.05, a price-to-earnings-growth ratio of 13.94 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the business earned $2.05 EPS. The company’s quarterly revenue was up 4.7% year over year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a $0.60 dividend. This represents a dividend of $2.40 on an annualized basis and a dividend yield of 5.93%. The ex-dividend date is Friday, July 5. Bristol-Myers Squibb’s payout ratio is -77.42%.

Institutional inputs and outputs

A number of institutional investors have recently made changes to their positions in BMY. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $27,000. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb in the 1st quarter valued at about $27,000. Accordant Advisory Group Inc bought a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 4th quarter valued at about $40,000. 76.41% of shares are owned by institutional investors.

About Bristol-Myers Squibb

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further reading

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.